Spyre Therapeutics (SYRE) Equity Ratio (2016 - 2025)
Historic Equity Ratio for Spyre Therapeutics (SYRE) over the last 11 years, with Q3 2025 value amounting to 0.9.
- Spyre Therapeutics' Equity Ratio rose 1600.18% to 0.9 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.9, marking a year-over-year increase of 1600.18%. This contributed to the annual value of 0.85 for FY2024, which is 5809.12% up from last year.
- As of Q3 2025, Spyre Therapeutics' Equity Ratio stood at 0.9, which was up 1600.18% from 0.85 recorded in Q2 2025.
- In the past 5 years, Spyre Therapeutics' Equity Ratio ranged from a high of 0.9 in Q3 2025 and a low of 1.18 during Q3 2023
- For the 5-year period, Spyre Therapeutics' Equity Ratio averaged around 0.56, with its median value being 0.76 (2021).
- In the last 5 years, Spyre Therapeutics' Equity Ratio tumbled by 26048.29% in 2023 and then skyrocketed by 20082.59% in 2024.
- Over the past 5 years, Spyre Therapeutics' Equity Ratio (Quarter) stood at 0.76 in 2021, then dropped by 7.4% to 0.71 in 2022, then dropped by 23.87% to 0.54 in 2023, then soared by 58.09% to 0.85 in 2024, then grew by 5.98% to 0.9 in 2025.
- Its last three reported values are 0.9 in Q3 2025, 0.85 for Q2 2025, and 0.85 during Q1 2025.